FibroGen (NASDAQ:FGEN) Announces Quarterly Earnings Results, Beats Expectations By $0.21 EPS

FibroGen (NASDAQ:FGEN) released its earnings results on Tuesday. The biopharmaceutical company reported ($0.17) EPS for the quarter, beating the consensus estimate of ($0.38) by $0.21, Zacks reports. The company had revenue of $46.33 million for the quarter, compared to analyst estimates of $34.00 million. During the same period in the previous year, the business posted ($0.52) EPS.

FibroGen Stock Performance

Shares of NASDAQ:FGEN traded down $0.06 during trading hours on Wednesday, hitting $0.33. 3,544,255 shares of the company’s stock traded hands, compared to its average volume of 2,230,193. The company’s fifty day simple moving average is $0.37 and its two-hundred day simple moving average is $0.72. The company has a market cap of $33.10 million, a price-to-earnings ratio of -0.30 and a beta of 0.72. FibroGen has a 52 week low of $0.18 and a 52 week high of $2.93.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on FGEN shares. William Blair restated a “market perform” rating on shares of FibroGen in a research report on Wednesday. StockNews.com initiated coverage on FibroGen in a report on Wednesday, November 6th. They issued a “hold” rating for the company.

FibroGen Company Profile

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.